Anders Martin-Löf
Vermögen: 113 124 $ am 31.05.2026
Vermögen: 113 124 $ am 31.05.2026
Anders Martin-Löf is currently serving as an Independent Director at Cantargia AB, a Director at Oncopeptides Incentive AB, a Director at Lisa Martin-Löf Konsultbyrå AB, a Director at Affibody Medical AB, and will be the Chief Financial Officer & Secretary at BioArctic AB starting in 2023.
Previously, he held the position of Chief Financial Officer & Deputy CEO at Oncopeptides AB from 2018 to 2021.
He also served as a Director of Investor Relations at Biovitrum AB, a Director at Sciencecap Stockholm AB, the CFO, Investor Relations & Press Contact at RaySearch Laboratories AB from 2014 to 2015, the Chief Financial Officer at Extenda AB, the Head of Investor Relations at Swedish Orphan Biovitrum AB from 2006 to 2007, the Chief Financial Officer at Wilson Therapeutics AB from 2015 to 2018, and the Chief Financial Officer at A3P Biomedical AB (publ).
Mr. Martin-Löf obtained his undergraduate degree from the University of Stockholm, his graduate degree from the Royal Institute of Technology, and another graduate degree from ENSIMAG.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.04.2025 | 2’500 ( 0% ) | 95 416 $ | 31.05.2026 | |
CANTARGIA AB 0.03% | 31.12.2024 | 75’000 ( 0.03% ) | 17 708 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CANTARGIA AB | Direktor/Vorstandsmitglied | 01.01.2018 |
| BIOARCTIC AB | Finanzdirektor/CFO | 01.06.2023 |
Lisa Martin-Löf Konsultbyrå AB | Direktor/Vorstandsmitglied | - |
Oncopeptides Incentive AB | Direktor/Vorstandsmitglied | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals services | Direktor/Vorstandsmitglied | 01.12.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOPEPTIDES AB | Finanzdirektor/CFO | 08.11.2021 |
| WILSON THERAPEUTICS AB | Finanzdirektor/CFO | 01.08.2018 |
| RAYSEARCH LABORATORIES AB | Finanzdirektor/CFO | 02.07.2015 |
| SWEDISH ORPHAN BIOVITRUM AB | Investor Relations Kontakt | 01.07.2007 |
| ░░░ ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░░░░░░░░░░ | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 16 |
|---|---|
RaySearch Laboratories AB
RaySearch Laboratories AB Packaged SoftwareTechnology Services Supplies computer software that improves the efficacy of radiation therapy for cancer | Technology Services |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals services | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
University of Stockholm
University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Royal Institute of Technology
Royal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ENSIMAG
ENSIMAG Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioArctic AB
BioArctic AB Pharmaceuticals: MajorHealth Technology Develops drugs for patients with disorders of the central nervous systems | Health Technology |
Extenda AB
Extenda AB Information Technology ServicesTechnology Services Provides information technology solutions | Technology Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Wilson Therapeutics AB
Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company focusing in treatment of Wilson disease | Health Technology |
Oncopeptides Incentive AB | |
Sciencecap Stockholm AB | |
Lisa Martin-Löf Konsultbyrå AB | |
A3P Biomedical AB (publ)
A3P Biomedical AB (publ) Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen